Respiratory Syncytial Virus (RSV) – Clinical Resources
2026 to 2027 RSV Season
Starting on October 1, 2026 through March 31, 2027 eligible infants and children will begin receiving nirsevimab injections. Updated Clinical Resources are available below.
Eligibility
Nirsevimab is publicly funded for infants and children who are residents of Saskatchewan and meet any of the following criteria:
- Infants born at less than 32 weeks gestation between January 1 and September 30, 2026
- Infants born at less than 36 weeks gestation between April 1 and September 30, 2026
- Infants born October 1, 2026 to March 31, 2027
- Children up to 24 months of age as of October 1, 2026 who are at increased risk of severe RSV disease entering their first or second RSV season with:
- Chronic lung disease (CLD) requiring chronic medical therapy in the six months prior to the start of RSV season, Hemodynamically significant congenital heart disease (CHD), Trisomy 21, Cystic Fibrosis (first season only), Immunodeficiency, Neuromuscular disease impairing the clearing of airway secretions, Severe congenital airway anomalies impairing the clearing of respiratory secretions
- OTHERS: Requires medical justification from the requesting MRP to be submitted to RSV Program for approval (first and second season)
Clinical Procedure
Learning Module
- Learning Modules Online Access Instructions - Search by name or number below
- • Nirsevimab RSV Learning Module (MC-LM-0034)
- ALERT: Log in to MyConnection prior to accessing any learning module to ensure completion is recorded in the system